The US Food and Drug Administration has approved the first once-monthly subcutaneous injection of risperidone (Perseris, Indivior) for the treatment of schizophrenia in adults. Perseris uses an ...

TITUSVILLE, N.J., Oct. 9 /PRNewswire-FirstCall/ -- Patients with schizophrenia now have a new administration option for RISPERDAL(R) CONSTA(R) ([risperidone] Long ...

The FDA has approved the injection of Risperdal Consta (risperidone long-acting injection, from Janssen) into the deltoid muscle of the arm for the treatment of schizophrenia. This approval was based ...

Purpose: The pharmacology, pharmaceutics, clinical efficacy, adverse effects, cost, and dosage and administration of long-acting risperidone injection are reviewed. Summary: Risperidone is the first ...

TEL AVIV, Israel & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext: MEDCL) today announced positive results for study TV46000-CNS-30072 (the ...

10 February 2004 – Davos – People with schizophrenia treated with RISPERDAL® CONSTA® [risperidone long-acting injection] are significantly less likely to be admitted to hospital than before they were ...

21 September 2003 – Prague – People with schizophrenia and other psychiatric disorders can switch with ease from previous antipsychotic medications to RISPERDAL® CONSTA (risperidone long acting ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a long-acting subcutaneous risperidone injection for the treatment of schizophrenia in adults.

The FDA has approved Risperdal Consta (risperidone long-acting injection, from Janssen) for use as monotherapy or as adjunctive therapy to lithium or valproate in the maintenance treatment of bipolar ...

Pharma major Lupin Ltd on Wednesday said it has received approval from the US health regulator for its generic version of risperidone for extended-release injectable suspension, used in the treatment ...

PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS--(BUSINESS WIRE)-- Regulatory News: Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext: MEDCL) today announced positive ...